作者
Goran Stanajic‐Petrovic,Mathilde Keck,Peggy Barbe,Apolline Urman,Evelyne Correia,Pierre Isnard,Jean‐Paul Duong Van Huyen,Khawla Chmeis,Sékou Siramakan Diarra,Stéfano Palea,Frédéric Théodoro,Anh Ly Nguyen,Florence Castelli,Alain Pruvost,Wenchao Zhao,Christiane Mendre,Bernard Mouillac,Frank Bienaimé,Philippe Robin,Pascal Kessler,Catherine Llorens‐Cortés,Denis Servent,Hervé Nozach,Bernard Maillère,Dong Guo,Charles Truillet,Nicolas Gilles
摘要
Vaptans were developed at the end of the previous century as V2R antagonists. Tolvaptan is the most prescribed vaptan for hyponatremia and the autosomal polycystic kidney disease (ADPKD). However, its use is not as widespread as it should be due to price issues, a narrow therapeutic window and some side effects. With the aim of discovering new efficient and safer V2R antagonists, we screened animal venoms and identified several interesting peptide toxins. Among them, MQ1 displayed such unique biological properties in that regard that it was the starting point for the development of a potential drug candidate.